Profile
Mark A. Demitrack is currently the Chief Medical Officer at Trevena, Inc. and a Member of the American College of Neuropsychopharmacology.
Previously, he served as the Medical Director-New Antidepressant Team at Lilly Research Laboratories.
From 2003 to 2017, he was the Chief Medical Officer & Vice President at Neuronetics, Inc. He also worked as the Vice President-Clinical Strategy at Roivant Sciences Ltd. from 2017 to 2018 and as the Assistant Vice President-Global Medical Affairs at Wyeth Pharmaceuticals, Inc. Dr. Demitrack completed his undergraduate degree at The Trustees of Columbia University in The City of New York and obtained his doctorate from Robert Wood Johnson Medical School.
Mark Demitrack active positions
| Companies | Position | Start |
|---|---|---|
| TREVENA, INC. | Chief Tech/Sci/R&D Officer | 20/05/2018 |
American College of Neuropsychopharmacology
American College of Neuropsychopharmacology Miscellaneous Commercial ServicesCommercial Services Operates as a neuron psychopharmacology school | Corporate Officer/Principal | - |
Former positions of Mark Demitrack
| Companies | Position | End |
|---|---|---|
| ROIVANT SCIENCES LTD. | Corporate Officer/Principal | 30/04/2018 |
| NEURONETICS, INC. | Chief Tech/Sci/R&D Officer | 30/04/2017 |
Wyeth Pharmaceuticals, Inc.
Wyeth Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Corporate Officer/Principal | - |
Lilly Research Laboratories
Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Engages in research and develops medicines | Corporate Officer/Principal | - |
Training of Mark Demitrack
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 8 |
|---|---|
Neuronetics, Inc.
Neuronetics, Inc. Medical SpecialtiesHealth Technology Develops and commercializes non-invasive therapies for psychiatric and neurological disorders | Health Technology |
Roivant Sciences Ltd.
Roivant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Operates as a holding company through its subsidiaries develops restorative therapies for autoimmune diseases | Health Technology |
The Trustees of Columbia University in The City of New York
The Trustees of Columbia University in The City of New York Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Robert Wood Johnson Medical School
Robert Wood Johnson Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lilly Research Laboratories
Lilly Research Laboratories Miscellaneous Commercial ServicesCommercial Services Engages in research and develops medicines | Commercial Services |
Trevena, Inc.
Trevena, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by central nervous system | Health Technology |
American College of Neuropsychopharmacology
American College of Neuropsychopharmacology Miscellaneous Commercial ServicesCommercial Services Operates as a neuron psychopharmacology school | Commercial Services |
Wyeth Pharmaceuticals, Inc.
Wyeth Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceutical products | Health Technology |
- Stock Market
- Insiders
- Mark Demitrack
















